KalVista Pharmaceuticals (KALV) versus Opiant Pharmaceuticals (OPNT) Head-To-Head Survey
KalVista Pharmaceuticals (NASDAQ: KALV) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.
Insider & Institutional Ownership
76.1% of KalVista Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.7% of Opiant Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by insiders. Comparatively, 63.8% of Opiant Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
KalVista Pharmaceuticals has a beta of 2.82, indicating that its share price is 182% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of -2.33, indicating that its share price is 333% less volatile than the S&P 500.
This table compares KalVista Pharmaceuticals and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares KalVista Pharmaceuticals and Opiant Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|KalVista Pharmaceuticals||$1.50 million||63.76||-$18.60 million||N/A||N/A|
|Opiant Pharmaceuticals||$18.45 million||3.24||$6.58 million||$0.42||68.79|
Opiant Pharmaceuticals has higher revenue and earnings than KalVista Pharmaceuticals.
This is a breakdown of current ratings and recommmendations for KalVista Pharmaceuticals and Opiant Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
KalVista Pharmaceuticals presently has a consensus target price of $27.00, suggesting a potential upside of 174.11%. Given KalVista Pharmaceuticals’ higher possible upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Opiant Pharmaceuticals.
Opiant Pharmaceuticals beats KalVista Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.